51 results about "Cholestasis" patented technology

The invention discloses Pediococcus pentosaceus G41, which is separated from rumen fluid of healthy adult dairy cows in a certain cattle farm in Changchun, has the advantages of high growth speed and strong acid production capacity, and can effectively relieve cholestatic liver injury. Experiments prove that the Pediococcus pentosaceus G41 reduces the activity of serum AST, ALT and GDH of a mouse with cholestatic liver injury, reduces the content of total bile acid in blood and liver, increases the content of total bile acid in excrement, and improves cholestatic and dirty injury caused by cholestatic.

The invention provides a preparation method of a cholestatic liver injury animal model, which comprises the following steps: on the basis that a mouse is fed with a feed containing 500IU / kg vitamin A for 8 weeks to cause deficiency of vitamin A in the mouse body, performing intragastric administration of alpha-naphthyl isothiocyanate (ANIT) at 50mg / kg for 4 weeks once a week, so as to obtain the cholestatic liver injury mouse model. The blood biochemical index ALT, the liver index, the pathological structure change of the liver tissue and the bile acid deposition of the liver tissue are more obvious. The cholestatic liver injury model prepared by the preparation method can avoid the influence of inconsistent dosage and unstable model in a conventional method, and can be applied to the research fields of molecular mechanism research of occurrence and development of cholestatic liver injury, finding of cholestatic liver injury treatment medicines and methods and the like.

The invention discloses a substituted aromatic heterocyclic compound containing a spiro skeleton as well as a preparation method and application thereof, and relates to the field of medicinal chemistry, in particular to the substituted aromatic heterocyclic compound containing the spiro skeleton or pharmaceutically acceptable salt of the substituted aromatic heterocyclic compound, a necessary composition containing the compounds and medical application of the substituted aromatic heterocyclic compound. The invention relates to an application of a monoacylglyceridase inhibitor, in particular to application of the monoacylglyceridase inhibitor as a monoacylglyceridase (MAGL) inhibitor in preparation of drugs for preventing and / or treating MAGL-related diseases. Comprise depression, schizophrenia, bi-directional disorder, dyskinesia, traumatic brain injury, neuroinflammation, Parkinson's disease, Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, anxiety disorder, pain, metabolic disorder, alcoholic fatty liver disease, non-alcoholic fatty liver disease, hepatic fibrosis, cholestasis, nephropathy and other related diseases.

Described are methods for treating alpha-1 antitrypsin deficiency (AATD) in a human patient in need of treatment, using pharmaceutical compositions that include AAT RNAi agents. The pharmaceutical compositions disclosed herein that include AAT RNAi agents, when administered to a human patient in need thereof, treat liver diseases associated with AAT deficiency such as chronic hepatitis, cirrhosis, increased risk of hepatocellular carcinoma, transaminitis, cholestasis, fibrosis, fulminant hepatic failure, and other liver-related diseases.

The present application provides a compound of formula (I), or an optical isomer thereof, a pharmaceutically acceptable salt, a solvated form, or a prodrug. The compound may modulate NTCP function for the prevention and / or treatment of HBV / HDV and hepatitis virus-related diseases, bile acid-related cholestasis disorders, metabolic disorders, and / or liver diseases. Additionally, the present application relates to a pharmaceutical composition comprising such a compound and a method for modulating NTCP.

To provide RNAi agents for inhibiting expression of the α-1 antitrypsin (AAT) gene, compositions including the AAT RNAi agents, and methods of using the same.SOLUTION: Also there are disclosed pharmaceutical compositions including one or more AAT RNAi agents together with one or more excipients capable of delivering the RNAi agents to living cells in vivo. The delivery of the AAT RNAi agents to liver cells in vivo inhibits AAT gene expression and treats diseases associated with AAT deficiency such as chronic hepatitis, cirrhosis, hepatocellular carcinoma, transaminitis, cholestasis, fibrosis, and fulminant hepatic failure.SELECTED DRAWING: Figure 9

The present disclosure provides methods and compositions for treating a disease or condition involving inflammation and / or fibrosis in the liver, e.g., metabolic dysfunction-associated steatohepatitis (MASH), metabolic dysfunction-associated steatotic liver disease (MASLD), primary biliary cholangitis, primary sclerosing cholangitis, alcoholic cirrhosis, hepatitis cirrhosis, cholestasis, autoimmune hepatitis, viral hepatitis B, viral hepatitis C, hemochromatosis, Wilson's disease, or alcoholic steatohepatitis, with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody.

The application discloses application of AML-12 exosomes in preparation of medicines for treating cholestatic liver injury, relates to the technical field of biological medicine, and discloses application of AML-12 cell-derived exosomes in preparation of medicines for preventing and treating ANIT-induced cholestatic liver injury; the treatment is manifested as reduction of alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase levels in serum. The application proves that the AML-12 cell-derived exosomes have a significant treatment effect on ANIT-induced cholestatic liver injury, successfully opens up the application of the biological preparation in a brand-new disease field, and fills the blank of the prior art; through in-vivo experiments, it is proved that AML-12 exosome treatment can significantly reduce liver cell injury markers and alkaline phosphatase, a key index of cholestasis, in serum of ANIT model mice, and improve pathological injury of liver tissue, thereby constituting a complete curative effect evidence chain from function to morphology.

The invention relates to the technical field of probiotics, and discloses a probiotic preparation for improving abnormal bile diseases of newborns. According to the probiotic preparation provided by the invention, lactobacillus fermentum CECT5716, bifidobacterium breve M-16V and bifidobacterium longum subsp. Longum BB536 in the list of strains for infants are selected as a product formula, and the probiotic preparation can be used for effectively improving abnormal bile diseases of newborns, including jaundice, hyperbilirubinemia and cholestasis, and can be used for preventing and treating the abnormal bile diseases of the newborns, such as jaundice, hyperbilirubinemia and cholestasis. The problems that in the prior art, safety is insufficient, pertinence is insufficient, and clinical requirements of complex illness conditions cannot be met are effectively solved.

The invention discloses an application of an RNAm6A modification level of PTGER4 in preparation of an ICP (inductively coupled plasma) auxiliary diagnosis kit. The RNA m6A modification level of the PTGER4 in placenta tissue and whole blood of an ICP patient is remarkably reduced, and the AUC modified by the RNA m6A of the PTGER4 in the whole blood is 0.844, so that the RNA m6A modification of the PTGER4 is a biomarker highly related to ICP attack, and a laboratory support can be provided for screening, diagnosis and treatment of ICP.

The invention provides a pharmaceutical composition for treating cholestatic liver injury, and the pharmaceutical composition contains an effective amount of Ferulic acid and Wogonin. The application creatively focuses on two key links in the cholestatic liver injury process, namely (1) bile acid excretion and (2) intestinal mucous barrier protection, a synergistic component of Ferulic acid and wogonin is provided, and the optimal ratio of Ferulic acid and wogonin is verified through an experimental system. Experiments prove that the cholestatic liver injury can be effectively improved by combined application of the Ferric acid and the Wogonin which are derived from traditional Chinese medicines; in addition, the effect of the medicine composition is obviously superior to the effect of independently using the Ferric acid or the Wogonin. Wide application prospects are realized.

The present invention provides a novel heterocyclic compound, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for preventing or treating an autotaxin activity-related disease containing the same as an active ingredient. The heterocyclic compound according to the present invention exhibits excellent inhibitory activity against autotaxin, and is useful for the treatment and prevention of fibrotic diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, metabolic diseases, cancer and cancer metastasis, eye diseases, cholestatic forms and other forms of chronic pruritus, and acute or chronic organ transplant rejection reactions, which are autotaxin-inhibiting related diseases.

The present disclosure relates to aromatic compounds and medical uses thereof, in particular to compounds of general formula (I): wherein R1, R2, R3, R4, R5, R6 and R7 may be selected from different substituents; n is 0, 1 or 2; and X is hydroxymethyl or a carboxylic acid or a derivative thereof, such as a carboxylate, such as a carboxylic ester, glyceride, anhydride, phospholipid, carboxamide, phospholipid, or a prodrug thereof; or pharmaceutically acceptable salts, solvates, solvates of the salts, or prodrugs thereof. The present disclosure also relates to pharmaceutical and lipid compositions comprising at least one compound according to the present disclosure, and to the use of such compounds as a medicament or for treatment, in particular for the treatment of diseases associated with metabolic and liver diseases, such as non-alcoholic fatty liver diseases and cholestasis diseases. (I)

The invention provides application of glycoursodeoxycholic acid in treating cholestasis type acute liver injury induced by podophyllotoxin, and relates to the field of chemical medicines. Glycine ursodeoxycholic acid as an HSPA9 micromolecule agonist can reduce synthesis of bile acid, promote excretion of the bile acid and improve the cholestasis condition by adjusting FXR / Cyp7a1 / BSEP bile acid metabolic pathway. Meanwhile, the glycoursodeoxycholic acid can improve oxidative stress injury, promote cell proliferation and reduce the cell apoptosis rate to a certain extent, so that pathological injury of the liver is improved, and a new choice is provided for treating related diseases accompanied by acute liver injury.

The invention discloses a cholestasis index-based liver cancer risk prediction model construction method, which comprises the following steps: collecting chronic HBV infected person data containing 16 parameters, carrying out desensitization, carrying out stratified random sampling to divide a data set, and carrying out two-stage screening to obtain HBsAg, ALT, ALP, GGT, PLT and AFP core features; after Min-Max Scaling processing, L1 regularization logistic regression is combined with grid search and 5-fold cross validation to construct the model, and the model constructed by the method is obviously superior to a traditional CU-HCC model and a REACH-B model, especially has higher recognition capability for early HBV-PLC, and can effectively reduce the missed diagnosis rate.

Provided herein are methods for treating cholestasis in a subject having a liver disease. The method includes administering to the subject an Apical Sodium-dependent Bile Acid Transporter (ASBTI). More specifically, the present invention relates to methods for treating cholestasis in a subject where the method includes administering an ASBTI to a subject at a dose of at least 10 μg / kg / day.

This invention discloses a veterinary drug composition containing Bupleurum chinense extract, its preparation method, and its application, belonging to the technical field of veterinary traditional Chinese medicine preparations. The composition consists of active ingredients (only saikosaponins a and d, in a mass ratio of 0.8–1.2:1, accounting for 5%–50% of the total content) and excipients (one or more of microcrystalline cellulose, magnesium stearate, and starch). The dosage form is tablets, granules, or powder, with each unit dose containing 5–20 mg of the total mass of both. In preparation, dried Bupleurum chinense roots are pulverized and enzymatically hydrolyzed with a 1:1 complex enzyme, ultrasonically extracted with an ethanol-sodium citrate mixture, purified with AB-8 macroporous resin, and freeze-dried to obtain saikosaponin powder. This powder is then mixed with the excipients and granulated, tableted, or packaged into the corresponding dosage form. This composition shows significant efficacy against fatty liver in chickens, hepatitis in pigs, and cholestasis in ducks, exhibiting stability, high purity, and high efficiency, providing a safe new option for the treatment of liver and gallbladder diseases in livestock and poultry.

According to the medicine for treating cholestatic liver injury and application, stevioside in the medicine provides an effective traditional Chinese medicine monomer component for treating cholestatic diseases, and the stevioside reduces the levels of bile acid TBA, total bilirubin TBIL and direct bilirubin DBIL in serum of cholestatic mice induced by BDL; the inflammatory response of BDL-induced cholestasis mice is improved; the effect of improving liver in-situ inflammation infiltration is achieved; new clinical indications of the stevioside are expanded, and the stevioside has a good application prospect.

The invention relates to inhibitors of the PKC signaling pathway for use in the treatment of septic cholestasis, wherein the inhibitors are targeted into the liver by a selective nanostructured delivery system, wherein the selective nanostructured delivery system comprises at least one polymethine dye and at least one polymer and / or at least one lipid and / or at least one virus-like particle, wherein the at least one polymethine dye is a symmetrical or asymmetrical polymethine.

The present disclosure relates to compounds of general formula (I): wherein R1, R2, R3, R4, R5, R6 and R7 can be selected from different substituents; n is 0, 1 or 2; and X is hydroxymethyl or a carboxylic acid or a derivative thereof, such as a carboxylate, such as a carboxylic acid ester, glyceride, anhydride, phospholipid, carboxamide, phospholipid, or a prodrug thereof; or a pharmaceutically acceptable salt, solvate, solvate of said salt, or a prodrug thereof. The present disclosure also relates to pharmaceutical compositions and lipid compositions comprising at least one compound according to the present disclosure, and to the use of such compounds as medicaments or for treatment, in particular for the treatment of diseases associated with metabolic diseases and liver diseases, such as non-alcoholic fatty liver disease and cholestatic diseases.

The present invention relates to a method of prevention, delay of progression or treatment of cholestasis and / or fibrosis associated with cholestasis.

The invention belongs to the technical field of biology, and particularly relates to a construction method and application of a loach cholestasis model.The standardized loach cholestasis model construction method is established in loaches for the first time, and the method comprises the steps that the loaches with the weight ranging from 6.37 g to 6.41 g are selected as animal models; continuously feeding animal feed containing 0.3 w / w%-0.4 w / w% of alpha-naphthyl isothiocyanate, feeding for 6-8 days to obtain an animal model, and during the feeding period, the ammonia nitrogen content of a feeding water body is less than 0.5 mg / L, the temperature is 24-28 DEG C, the pH is 7.4-7.6, the dissolved oxygen content is greater than 7.0 mg / L, the nitrite content is less than 0.05 mg / L, and one third of the water body is replaced every day. The construction method of the loach cholestasis model is easy to operate, the modeling rate is as high as 92.96%, the model is stable, and the detection method is multi-dimensional.

The present disclosure relates to compounds of the general formula (I):wherein R1, R2, R3, R4, R5, R6, and R7 may be chosen from different substituents; n is 0, 1, or 2; and X is a hydroxymethyl or a carboxylic acid or a derivative thereof, such as a carboxylate, such as a carboxylic ester, a glyceride, an anhydride, a phospholipid, a carboxamide, a phospholipid, or a prodrug thereof; or a pharmaceutically acceptable salt, solvate, solvate of such salt or a prodrug thereof. The present disclosure also relates to pharmaceutical compositions and lipid compositions comprising at least one compound according to the present disclosure, and to such compounds for use as medicaments or for use in therapy, in particular for the treatment of diseases related to metabolic diseases and liver diseases, such as non-alcoholic fatty liver disease and cholestasis diseases.

The invention discloses application of a gold nanocluster in preparation of a medicine for treating sepsis liver injury. Animal and cell experiments prove that the gold nanocluster has a remarkable treatment effect on sepsis liver injury (SLI), and the levels of inflammatory factors in serum of model animals and aspartate aminotransferase serving as a liver injury marker can be reduced; in an in-vitro model, the cluster compound can relieve hepatocyte mitochondrial dysfunction caused by cholestasis and bile acid metabolism disorder and promote cell survival, so that the effect of protecting hepatocytes is achieved.

The invention discloses a method for detecting metabolite containing phosphate radicals, which is characterized in that a mass spectrum label with stable and characteristic chlorine isotope distribution is introduced through a chlorination reagent derivatization strategy, so that a derivatization product can be subjected to rapid and high-specificity preliminary identification based on primary mass spectrum data. By combining with an automatic data mining program specially developed for this purpose, high-throughput and accurate screening and locking of potential phosphate radical-containing metabolites from massive and complex non-targeted metabonomics original data are realized, and the data analysis efficiency and reliability are greatly improved. The method is successfully applied to analysis of actual biological samples such as cholestasis disease models, efficient identification and accurate quantification of various key metabolites such as nucleotide and sugar phosphoric acid are achieved, disturbance of related metabolic pathways is disclosed, and a powerful innovative analysis tool is provided for disease mechanism research and biomarker discovery.

The invention discloses shRNA (short hairpin ribonucleic acid) capable of specifically inhibiting circTNK2-Mus expression and application of the shRNA. The nucleotide sequence of the shRNA is shown as SEQ ID NO. 5. The invention also provides an oligonucleotide sequence (as shown in SEQ ID NO.3-4) for coding the shRNA, a recombinant LV3 lentivirus plasmid containing the sequence, a recombinant lentivirus packaged by the recombinant LV3 lentivirus plasmid, a pharmaceutical composition containing the virus and application of the recombinant lentivirus. Experiments prove that in a cholestasis-induced hepatic fibrosis animal model, the expression of circTNK2-Mus in liver tissues can be efficiently and specifically knocked down by performing caudal vein injection on the recombinant lentivirus, the pathological indexes of fibrosis are remarkably improved, and the occurrence and development of hepatic fibrosis are effectively prevented. The invention provides a brand-new circRNA target spot and a gene therapy candidate drug with great potential for hepatic fibrosis.

The invention relates to the technical field of biological medicines, in particular to a method for improving cholestatic hepatic fibrosis by using gastrodin. Comprising the following steps that a therapeutically effective dose of gastrodin is applied to mammals suffering from cholestatic hepatic fibrosis, the administration dosage of the gastrodin is 12.5-150 mg / kg / day, and the administration period is 2-4 weeks. The invention provides a method for improving cholestatic hepatic fibrosis by using gastrodin, which realizes multi-target regulation and control of the fibrosis process through a specific dosage and period administration scheme.

The invention provides a medicine beneficial to liver cell proliferation and application. The rifampicin in the medicine has a protective effect on CCl4-induced acute liver injury of mice and bile duct ligation BDL-induced cholestatic liver injury, and can improve liver inflammation infiltration, promote liver cell proliferation and effectively drive liver repair. Besides, under the liver steady-state condition, rifampicin administration can induce liver cell proliferation, the liver / body weight ratio is remarkably increased, and liver cell proliferation under the basic state can be promoted. Therefore, rifampicin plays a key role in promoting liver regeneration in maintaining the physiological state of the liver and repairing liver injury, and is a potential drug for promoting liver regeneration.

The invention relates to inhibitors of the PKC signaling pathway for use in the treatment of septic cholestasis, wherein the inhibitors are targeted into the liver by a selective nanostructured delivery system, wherein the selective nanostructured delivery system comprises at least one carbohydrate targeting moiety and at least one polymer and / or at least one lipid and / or at least one virus-like particle.

Provided herein are methods for treating cholestasis in a subject having a liver disease. The method includes administering to the subject an Apical Sodium-dependent Bile Acid Transporter (ASBTI). More specifically, the present invention relates to methods for treating cholestasis in a subject where the method includes administering an ASBTI to a subject at a dose of at least 10 μg / kg / day.